Ding Yanping, Researcher and Vice President of R&D at Beijing Immunochina Pharmaceuticals Co., Ltd., has more than ten years of experience in basic and translational research on gene therapy and immune cell therapy. At Immunochina, she led her team in establishing a competitive CAR-T cell therapy technology platform and product pipeline covering hematologic malignancies, solid tumors, and autoimmune diseases. The CAR-T products developed under her leadership have received five clinical trial approvals. She has published 40 SCI-indexed papers, filed more than 30 patent applications, and served as principal investigator on five national-level research projects.